What GLP-1 biosimilars does Amogen manufacture?

Amogen manufactures semaglutide and liraglutide biosimilar APIs using Saccharomyces cerevisiae recombinant fermentation at Plant 1, Hyderabad. Semaglutide is currently in Phase 1 clinical development targeting Q4 2026 first patient.

What is Amogen Pharma's manufacturing capacity?

Amogen operates 980 Kg total GLP-1 fermentation capacity at Plant 1, Hyderabad — comprising five 15KL fermenters and two 1KL fermenters, making it one of the largest dedicated GLP-1 API facilities in India.

Which markets is Amogen open to partnering in?

Amogen is open to biosimilar API supply and licensing partnerships across India, GCC, ASEAN, Canada, selected Africa and CIS, selected LATAM, European Union and North America.

Why does Amogen use Saccharomyces cerevisiae instead of E. coli?

Amogen's S. cerevisiae expression system mirrors the innovator's host system used by Novo Nordisk, delivering salt-free APIs with correct higher-order structure and solubility at commercial scale above 1000 Kg — advantages that E. coli and synthetic SPPS routes cannot replicate.

What does Amogen provide to biosimilar partners?

Amogen provides drug substance API supply, drug product in pen or cartridge format, analytical packages for DS and DP, ICH-compliant pre-clinical toxicology reports, regulatory and market access support, and long-term volume-linked pricing with secured GLP-1 capacity.

Home›About Amogen

Building India's largest recombinant peptide API company.

Science built in India. Partnerships built for the world. We turn recombinant complexity into commercial-scale supply for global pharmaceutical partners.

Amogen at a glance

From a single facility in Hyderabad, Amogen is building the scientific and manufacturing foundation that global pharmaceutical partners need to compete in high-value biosimilar markets.

2020

Founded

Hyderabad, India

70+

Employees

84% in research & development and manufacturing functions

15 yrs

Avg. R&D Expertise

Across key scientific personnel with a platform that has delivered two drugs to market.

980 Kg

GLP-1 Fermentation Output

Plant 1, Hyderabad — 5 × 15KL production fermenters

10+

Active Programs

GLP-1, insulin and immunology biosimilar programs

$40M+

Invested to date

In platform, pipeline and manufacturing infrastructure

Explore our Pipeline

OUR VISION

To be the world's leading recombinant biosimilar platform — where scientific rigour, manufacturing excellence and long-term partnerships make high-barrier biosimilars accessible at global scale.

OUR MISSION

To combine proprietary fermentation technology, deep regulatory expertise and long-term supply commitment into partnerships that help pharma companies compete and win in high-value biosimilar markets globally.

LEADERSHIP

The team behind the platform.

75+ years of combined experience in science, manufacturing and biopharmaceutical strategy.

Our leadership

P.V.S.N. Raju

Chairman & MD

Seasoned Entrepreneur & Engineering Excellence

P. Akhilesh Raju

Chief Executive Officer

MBA · Anglia Ruskin

Dr. T Devi Kalyan

Chief Operating Officer

PhD · DRDO

Biological EDr. Reddy's

Harmeet Lamba

Advisor

MBA · Wharton BS

RanbaxyDr. Reddy's

Dr. Manpreet Singh

Vice President, BD

PhD · NIPER

Dr. Reddy'sAurisco

OUR PRINCIPLES

How we work is as important as what we make.

Every scientific decision, every capacity investment, and every partnership commitment at Amogen is shaped by these five principles.

Our Principles

Amogen scientist conducting peptide biosimilar research at Plant 1 Hyderabad

Our Principles are the foundational building blocks of who we are as a company. They are woven into our decisions, guide our actions and remind us that in this industry, how you work matters as much as what you make.

P.V.S.N RAJU